References
- Vassallo RR Jr. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol 2007;14:655–63.
- Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004;103:333–9.
- Kerkhoffs JL, Eikenboom JC, van de Watering LM, et al. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 2008;48:1959–65.
- Doughty HA, Murphy MF, Metcalfe P, et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994;66:200–5.
- Slichter SJ, Davis K, Enright H, et al. Factors affecting posttranfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106–14.
- Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008;142:348–60.
- Daly PA, Schiffer CA, Aisner J, Wiernik PH. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980; 243:435–8.
- Yankee RA, Grumet FC, Rogentine GN. Platelet transfusion: the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 1969;281:1208–12.
- The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861–9.
- AuBuchon JP, Leach MF. Investigating the possibility of drug-dependent platelet antibodies. Immunohematology 2009;25:136–140.
- Cooling L. ABO and platelet transfusion therapy. Immunohematology 2007;23:20–33.
- [No authors listed.] Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors. Vox Sang 2003;84:73–88.
- Heal JM, Blumberg N, Masel D. An evaluation of cross-matching, HLA and ABO matching for platelet transfusions to refractory patients. Blood 1987;60:23–30.
- Petz LD. The HLA system and platelet transfusion. In: Murphy S, ed. The HLA system: basic biology and clinical applications. Bethesda, MD: American Association of Blood Banks, 1999.
- Curtis BR, McFarland JG. Detection and identification of platelet antibodies and antigens in the clinical laboratory. Immunohematology 2009;25:125–135.
- Semana G, Zazoun T, Alizahed M, et al. Genetic susceptibility and anti-human platelet antigen 5b alloimmunization: role of class II and TAP genes. Hum Immunol 1996;46:114–19.
- Blanchette VS, Chen L, de Friedberg ZS, et al. Alloimmunization to the PlA1 platelet antigen: results of a prospective study. Br J Haematol 1990;74:209–15.
- Norton A, Allen DL, Murphy MF. Review: platelet alloantigens and antibodies and their clinical significance. Immunohematology 2004;20:89–102.
- Curtis BR, Ali S, Glazier AM, et al. Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal alloimmune thrombocytopenia and brief review of the literature. Transfusion 2002;42:1173–9.
- Taaning E, Sinonsen AC, Hjelms E, et al. Platelet alloimmunization after transfusion. Vox Sang 1997;72:238–41.
- Kiefel V, Konig C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001;41:766–70.
- Kickler T, Kennedy SD, Braine HG. Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 1990;30:622–5.
- Legler TJ, Fischer I, Dittmann J, et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol 199;74:185–9.
- Kurz M, Greinix H, Hocker P, et al. Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders. Br J Haematol 1996;95:564–9.
- Godeau B, Fromont P, Seror T, et al. Platelet alloimmunization after multiple transfusions: a prospective study of 50 patients. Br J Haematol 1992;81:395–400.
- Uhrynowska M, Zupanska B. Platelet-specific antibodies in transfused patients. Eur J Haematol 1996;56:248–51.
- McGrath K, Wolf M, Bishop J, et al. Transient platelet and HLA antibody formation in multitransfused patients with malignancy. Br J Haematol 1988;68:345–50.
- Murphy MF, Metcalfe P, Ord J, et al. Disappearance of HLA and platelet-specific antibodies in acute leukaemia patients alloimmunized by multiple transfusions. Br J Haematol 1987;67:255–60.
- McFarland JG. Alloimmunization and platelet transfusion. Semin Hematol 1996;33:315–28.
- Schnaidt M, Northoff H, Wernet D. Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients. Transfus Med 1996;6:111–14.
- Sanz C, Freire C, Alcorta I, et al. Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion 2001;41:762–5.
- Pappalardo PA, Secord AR, Quitevis P, et al. Platelet transfusion refractoriness associated with HPA-1a (PlA1) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion 2001;41:984–7.
- Fujino H, Ohta K, Taniue A, et al. Primary refractoriness to platelet transfusion caused by Naka antibody alone. Vox Sang 2001;81:42–4.
- Lo SC, Chang JS, Lin SW, Lin DT. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients. Transfusion 2005;45:761–5.
- Ertel K, Al-Tawil M, Santoso S, Kroll H. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005;45:366–73.
- Berry JE, Murphy CM, Smith GA, et al. Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens. Br J Haematol 2000;110:735–42.
- Semple JW, Speck ER, Milev YP, et al. Indirect allorecognition of platelet by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation. Blood 1995; 86:805–12.
- Sayeh E, Aslam R, Speck ER, et al. Immune responsiveness against allogeneic platelet transfusions is determined by the recipient’s major histocompatibility complex class II phenotype. Transfusion 2004;44:1572–8.
- Lucas GF, Rogers SE. Evaluation of an enzyme-linked immunosorbent assay kit (GTi PakPlus) for the detection of antibodies against human platelet antigens. Transfus Med 1999;9:63–7.
- Allen D, Ouwehand WH, de Haas M, et al. Interlaboratory variation in the detection of HPA-specific alloantibodies and in molecular HPA typing. Vox Sang 2007;93:316–24.
- Lucas GF, Metcalfe P. Platelet and granulocyte glycoprotein polymorphisms. Transfus Med 2000;10:157–74.
- Cserti-Gazdewich CM, Dzik WH, Dorn ME, et al. Quantitation of CD36 (platelet glycoprotein IV) expression on platelets and monocytes by flow cytometry: application to the study of Plasmodium falciparum malaria. Cytometry B Clin Cytom 2009;76:127–34.